Table 3.
Cox proportional hazards regression analysis for risk of VL>400 copies/ml for crude and adjusted models after multiple imputation of all covariates
| Crude model |
Adjusted mode |
AICw |
||||
|---|---|---|---|---|---|---|
| Characteristic | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Lopinavir, mg/l | 0.96 (0.93, 0.98) | 0.005 | 0.96 (0.94, 0.99) | 0.019 | 0.96 (0.93, 0.99) | 0.005 |
| Age | ||||||
| >10 months | Reference | – | Reference | – | – | – |
| <10 months | 1.07 (0.75, 1.52) | 0.70 | 1.14 (0.80, 1.62) | 0.46 | – | – |
| Pretreatment WAZ | ||||||
| Normal | Reference | – | Reference | – | – | – |
| Moderate | 1.06 (0.75, 1.48) | 0.72 | 0.91 (0.61, 1.33) | 0.63 | – | – |
| Severe | 1.87 (0.61, 1.25) | 0.45 | 1.15 (0.77, 1.72) | 0.49 | – | – |
| Pretreatment HAZ | ||||||
| Normal | Reference | – | Reference | – | Reference | – |
| Moderate | 2.24 (1.17, 4.28) | 0.015 | 2.20 (1.18, 4.09) | 0.012 | 2.19 (1.19, 4.05) | 0.011 |
| Severe | 2.92 (1.69, 5.03) | 0.0001 | 2.83 (1.66, 4.82) | 0.0001 | 2.83 (1.67, 4.78) | 0.0001 |
| Pretreatment log10 VL | ||||||
| <5 | Reference | – | Reference | – | Reference | – |
| >5 | 1.62 (0.77, 3.44) | 0.21 | 1.56 (0.91, 3.54) | 0.27 | 1.58 (0.72, 3.44) | 0.252 |
| Pretreatment CD4% | ||||||
| >25% | Reference | – | Reference | – | – | – |
| <25% | 1.02 (0.68, 1.53) | 0.91 | 1.09 (0.73, 1.65) | 0.65 | – | – |
| WHO stage | ||||||
| Early | Reference | – | Reference | – | – | – |
| Moderate | 1.22 (0.70, 2.13) | 0.47 | 1.21 (0.69, 2.01) | 0.49 | – | – |
AICw, Akaike's information criterion with inverse probability weights; CD4%, CD4+ T-cell percentage; HAZ, height-for-age z-score; VL, viral load; WAZ, weight-for-age z-score.